RIKEN suspends first clinical trial involving induced pluripotent stem cells

  title={RIKEN suspends first clinical trial involving induced pluripotent stem cells},
  author={Ken Garber},
  journal={Nature Biotechnology},
  • K. Garber
  • Published 1 September 2015
  • Biology, Medicine
  • Nature Biotechnology
VOLUME 33 NUMBER 9 SEPTEMBER 2015 NATURE BIOTECHNOLOGY autologous transplants, which would have been much more informative. “There’s only been one patient with the autologous, which is a shame,” says Pete Coffey, a stem cell researcher at University College London. “An N of one is never good, that’s for sure.” For RIKEN’s future allogeneic trial, cells will come from CiRA, which is developing a bank of iPSCs from consenting individuals who have already donated to cord blood or peripheral blood… 
Adapting Cord Blood Collection and Banking Standard Operating Procedures for HLA-Homozygous Induced Pluripotent Stem Cells Production and Banking for Clinical Application
The main aspects to be considered to define standard operation procedures (SOPs) for the creation of an induced pluripotent stem cell (iPSC) bank using cord blood (CB)—or similar cell type—bank guidelines for clinical aims are discussed.
Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges
Recent progress toward clinical translation of autologous iPSC‐based cell therapies is highlighted, and technological advancements that would reduce the cost and complexity of autOLOGous i PSC-based cell therapy production are highlighted, enabling autologously iPSCs‐based therapies to become a more commonplace treatment modality for patients.
Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation
This review provides a perspective on the iPSC potential for cell therapies, particularly for hematological applications, and highlights some of the requirements and obstacles to be overcome before translating these cells from research to the clinic.
The translational potential of human induced pluripotent stem cells for clinical neurology
The translational potential of hiPSCs in clinical neurology and the importance of integrating this approach with complementary model systems to increase the translational yield of preclinical testing for the benefit of patients is highlighted.
Age Is Relative—Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality
The data would suggest that donor age does not limit iPSC application for modelling genetic diseases nor regenerative therapies, and open questions remain, e.g., regarding the potential tumourigenicity of iPSCs-derived cells and the impact of epigenetic pattern retention.
Concise Review: Molecular Cytogenetics and Quality Control: Clinical Guardians for Pluripotent Stem Cells
A set of standards to be utilized when preparing iPSCs for clinical use are recommended to maximize patient safety and the creation of haplobanks that provide major histocompatibility complex matching is recommended to improve allogeneic stem cell engraftment.
High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos
The present study reports the successful derivation of highest-quality clinical-grade hESC lines from fresh poor-quality surplus human embryos generated in a GMP-grade IVF laboratory, an important step towards more widespread application of regenerative medicine therapies.
iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
The potential of iPSC in the treatment of human disease is evaluated in the light of what is known about the reprogramming process, the behavior of cells in culture, and the performance of i PSC in pre-clinical studies.
Clinical potential of human-induced pluripotent stem cells
The clinical potential of human iPS cells is reviewed and which are the most suitable approaches to overcome or minimize risks associated with the application of iPS cell-derived cell therapies are evaluated.


Stem cells: The dark side of induced pluripotency
Induced pluripotent stem cells have great therapeutic potential. But genomic and epigenomic analyses of these cells generated using current technology reveal abnormalities that may affect their safe